Celecoxib in Treating Patients With Bladder Cancer

Criteria:

* No concurrent radiotherapy
* No prior angioplasty
* No concurrent chemotherapy
* No concurrent oral or IV corticosteroids for more than 2 consecutive weeks or orally inhaled corticosteroids for more than 4 consecutive weeks during any 6 month period of the study
* Chronic nasally inhaled steroids allowed provided patient agrees to use mometasone or, in countries where mometasone is not available, fluticasone
* No prior coronary bypass surgery
* At least 30 days since prior investigational medication
* No other prior malignancy within the past 5 years except:
* No prior pelvic radiotherapy
* Histologically proven superficial transitional cell carcinoma of the bladder at high risk for recurrence, meeting 1 of the following staging criteria:
* Stage Ta (grade 3 OR multifocal OR at least 2 occurrences, including current tumor, within the past 12 months)
* Stage T1 (any grade)
* Stage Tis
* Patients with Ta or T1 lesions must have undergone complete transurethral resection of bladder tumor within the past 9 months
* No carcinoma involving the prostatic urethra or upper urinary tract
* Must have received the following prior to randomization:
* Induction course of BCG comprising 6 weekly intravesical doses (at least 4 doses if BCG intolerant)
* Additional induction courses of BCG allowed
* Maintenance course of BCG comprising 3 weekly doses (at least 1 dose if BCG intolerant)
* No evidence of disease by cystoscopy (with or without biopsy) and bladder cytology prior to initiation of maintenance BCG
* Concurrent interferon allowed
* Zubrod 0-2 or ECOG 0-2
* WBC at least 3,000/mm\^3
* Hemoglobin at least lower limit of normal
* Platelet count at least 125,000/Mm\^3
* No significant bleeding disorder
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* SGOT and SGPT no greater than 1.5 times ULN
* No chronic or acute hepatic disorder
* Creatinine no greater than 1.5 times ULN
* No chronic or acute renal disorder
* Normal kidneys and ureters on imaging study within the past 9 months
* No active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
* No active pancreatitis
* No esophageal, gastric, pyloric channel, or duodenal ulceration that was diagnosed or treated within the past 30 days
* No history of cardiovascular disease, including any of the following conditions:
* Stroke
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No other medical or psychological condition that would preclude study participation
* No hypersensitivity or adverse reactions to sulfonamides, cyclooxygenase (COX)-2 inhibitors, salicylates, or other NSAIDs
* Nonmelanomatous skin cancer cured by excision
* Carcinoma in situ of the cervix
* Stage 0 chronic lymphocytic leukemia
* Other malignancy for which patient has no current evidence of disease, has received no therapy within the past 6 months, has no concurrent or planned therapy, and has an expected disease-free survival of at least 5 years
* No concurrent immunotherapy
* At least 2 weeks since prior aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) except cardioprotective dose (no greater than 100 mg/day) of aspirin
* No concurrent chronic NSAIDs except oral cardioprotective dose (no greater than 100 mg/day) of aspirin
* Concurrent chronic use is defined as a frequency of at least 3 times per week for more than 2 consecutive weeks per year
* No other concurrent investigational drug
* No other concurrent systemic therapy
* No concurrent lithium or fluconazole
* No other concurrent hormonal therapy except hormone replacement (i.e., estrogen or thyroid hormone replacement)
* Myocardial infarction
* Angina
* Congestive heart failure